June 7, 2017
Grünenthal buys AstraZeneca’s migraines drug
AstraZeneca has signed an agreement with Grünenthal for the global rights to Zomig (zolmitriptan), the drug indicated for the acute treatment of migraines and cluster headaches, outside Japan.